Is Entresto (sacubitril/valsartan) safe in patients with systolic blood pressure below 100 mmHg?

Entresto is Safe and Should Be Used in Patients with Systolic BP Below 100 mmHg

Yes, Entresto (sacubitril/valsartan) is safe and effective in patients with systolic blood pressure below 100 mmHg, provided they are asymptomatic or have only mild symptoms. The most recent 2025 European Heart Failure Association guidelines explicitly state that low BP should not prevent optimization of guideline-directed medical therapy with Entresto 1.

Key Evidence Supporting Safety

PARADIGM-HF Trial Data

The landmark evidence comes from post-hoc analysis of PARADIGM-HF, which demonstrated that sacubitril/valsartan benefits were consistent across all baseline SBP categories, including those <110 mmHg 1. Critically, patients in the lowest SBP strata (95-110 mmHg) actually experienced a mild BP increase over follow-up rather than further decline 1. This paradoxical BP rise likely reflects improved cardiac output from better heart function.

Among 8,399 patients enrolled:

• 16% experienced asymptomatic hypotension
• 11.1% experienced symptomatic hypotension
• Efficacy and safety were maintained regardless of hypotension occurrence 1

Real-World Evidence

Multiple real-world studies confirm safety in low BP populations:

• A 2023 observational study of 117 HFrEF patients found that 52.4% with baseline SBP <100 mmHg successfully reached target Entresto doses at 6 months 2
• Patients with SBP <100 mmHg showed a 7.5 mmHg increase in SBP (versus an 11.5 mmHg decrease in those with SBP ≥100 mmHg) 2
• No significant differences in symptomatic hypotension, renal dysfunction, hyperkalemia, or other adverse events between BP groups 2

Clinical Management Algorithm

For Asymptomatic Patients (SBP <100 mmHg)

Initiate Entresto with confidence using this approach:

1. Start at lowest dose (24/26 mg or 49/51 mg twice daily) 1
2. Up-titrate gradually over 6 weeks rather than 3 weeks - this improves tolerability in lower BP patients 3
3. Monitor closely with weekly visits during titration 1
4. Expect BP to stabilize or increase as cardiac function improves 1, 2

For Symptomatic Patients

Distinguish between problematic and benign symptoms:

• Mild dizziness on standing: Educate patient that this is expected, transient, and associated with life-prolonging therapy. Continue Entresto 1
• Severe symptoms (SBP <80 mmHg, significant orthostatic hypotension, persistent fatigue/dizziness): Investigate other causes first before attributing to Entresto 1

Critical Pitfall to Avoid

Do not automatically assume low BP in stable patients is caused by Entresto. If a patient is clinically stable on optimal therapy but develops low BP, the 2025 HFA guidelines emphasize this is unlikely to be directly caused by guideline-directed medical therapy 1. Instead:

1. Assess for congestion status (clinical exam, lung ultrasound, cardiac ultrasound)
2. Reduce diuretics first if no congestion present 1
3. Evaluate for other causes: new alpha-blockers for BPH, valvular disease, myocardial ischemia, non-cardiac causes 1

Dose Titration Strategy

The FDA label excludes patients with SBP <100 mmHg from initial trials 4, but real-world evidence and 2025 guidelines supersede this conservative exclusion. Asian populations have successfully used even lower starting doses:

• 12/13 mg twice daily as initial dose in patients with very low BP 5
• This "tiny dose" approach enhanced tolerability and reduced discontinuation rates 5
• Still achieved significant LVEF improvement (35.4% to 43.0%) and NT-proBNP reduction 5

Safety Profile

Hypotension is the most common adverse event but rarely requires discontinuation:

• Japanese post-marketing surveillance: 4.7% experienced hypotension as an ADR, but discontinuation rate was only 1.0% 6
• PIONEER trial: 15% symptomatic hypotension in treatment group vs 12.7% in placebo group 1
• Most hypotension events are asymptomatic and do not require intervention 1

When to Exercise Caution

Acute heart failure setting requires more vigilance:

• PIONEER trial required SBP >100 mmHg for previous 6 hours and clinical stability before initiation 1
• Wait until patient is hemodynamically stable (no escalating diuretics or inotropes for 24 hours) 1
• Start at low dose in recently hospitalized patients 1

Bottom Line

The 2025 HFA consensus statement is unequivocal: low BP should not hinder optimization of guideline-directed medical therapy with Entresto 1. The evidence demonstrates that patients with SBP <100 mmHg not only tolerate Entresto safely but often experience BP increases as their cardiac function improves. Use gradual up-titration, close monitoring, and patient education about transient symptoms to maximize success rates exceeding 70% even in this lower BP population 3.